Seladelpar for Treatment of PBC

Author(s):

Nancy Reau, MD,John Vierling, MD, FACP, FAASLD, AGAF

Key Takeaways

Seladelpar demonstrates sustained efficacy in improving liver biochemistry and symptom relief in primary biliary cholangitis (PBC) over long-term use.
The drug modulates lipid metabolism and inflammation, crucial mechanisms in managing PBC, enhancing its therapeutic potential.
Seladelpar maintains a favorable safety profile with minimal adverse effects, supporting its viability as an alternative treatment for PBC.
Long-term data reinforce seladelpar's role in addressing unmet clinical needs in PBC, offering a promising option beyond existing therapies.

The panel of experts review the long-term data on the recently FDA-approved PPAR-δ agonist seladelpar for primary biliary cholangitis (PBC), focusing on its efficacy, safety, and impact on liver biochemistry markers over time.